## Value in Health's Top Cited Papers from 2015: A Year in Review





Michael F. Drummond, MCom, DPhil, University of York, Heslington, York, UK; and C. Daniel Mullins, PhD, University of Maryland, Baltimore, MD, USA, Co-Editors-in-Chief, Value in Health

As Editors, we're always interested to see how the articles we publish in *Value in Health* are used to inform new research in the field. A measure of a journal's impact in the scientific literature is to see how many times those articles are cited by other researchers in the field. We feel that it is important that we share this information with our members to give you a sense of the papers and topics that are generating the most interest in the field. So, it seems a natural time of the year that we take a look back to see how the articles we've published in 2015 have performed in scientific literature.

A list of the top 10 most cited papers published in Value in Health in 2015 are listed in the sidebar to the right. As you'll see, three of the top-cited papers are reports from the ISPOR Good Practices Task Forces. The top-cited paper by Ramsey, et al. is an updated report on cost-effectiveness analysis in clinical trials. This report provides updated recommendations reflecting advances in areas related to trial design, database design and management, and analysis and reporting of results. The other two Task Force reports that were highly cited include a two-part series on simulation modeling. These reports by Marshall, et al. provide an overview of how to select and apply simulation modeling methods in health care delivery research. Historically, the ISPOR Good Practices Task Force Reports have consistently appeared on the list of top-cited articles. The number of citations these reports receive is a testament to the good work our members are doing to establish ISPOR as the source for guidance reports on good practices in the field of health economics and outcomes research.

The third most cited paper in 2015 is a commentary from Bill Crown that discusses the need for better analytic methods to keep pace with the evolving use of big data in health care. Two other papers on the list analyze the use of patient-reported outcomes in scientific studies. The paper by Blome and Augustin (ranked 4th on the list) examines bias in the prospective versus retrospective measurement of changes in quality of life data. The paper by Janssens, et al. evaluates 35 generic multidimensional patient-reported outcome measures for children and young adults.

Economic evaluations, including cost-utility analyses, continue to represent a major component of the papers published in *Value in Health*. Two other highly cited papers, both authored by Peter Neumann and colleagues from Tufts Medical Center, examine the growth in the use of cost-utility analyses in the literature. The number of publications continues to grow, the largest percentage growth being in papers from low and middle-income countries, albeit from a low base. The final two papers in the issue are representative of the types of economic and comparative effectiveness analyses that readers come to expect in *Value in Health*. The paper by Bouwmans, et al, ranked 5th on the list, aims to develop a standardized instrument for measuring and valuing productivity losses. And the paper by Cope, et al. critically appraises network meta-analyses of the efficacy and safety of new oral anticoagulants.

We hope that you will take the time to revisit some of these papers that were published in *Value in Health*—perhaps you will join the many others who have cited these works to inform future studies that advance the use, understanding, and application of health economics and outcomes research. Good reading!

## TOP 10 MOST CITED PAPERS PUBLISHED IN *VALUE IN HEALTH* IN 2015

A journal's Impact Factor is calculated by dividing the number of citations in the Journal Citation Report year by the total number of articles published in the two previous years. These top 10 papers are coming to the end of the first year of their two-year citation window.

1 Cost-Effective Analysis Alongside Clinical Trials II: An ISPOR Good Research Practices Task Force Report

Sullivan SD, Willke RJ, Glick H, et al. *Volume 18 Issue 2 161-172* 

2 Applying Dynamic Simulation Modeling Methods in Health Care Deliver Research: The SIMULATE Checklist: Report of the ISPOR Simulation Modeling Emerging Good Practices Task Force Marshall DA, Burgos-Liz L, Ijzerman MJ, et al.

Volume 18 Issue 1 6-16

3 Potential Application of Machine Learning in Health Outcomes Research and Some Statistical Cautions

Crown WH.

Volume 18 Issue 2 137-140

4 Measuring Change in Quality of Life: Bias in Prospective and Retrospective Evaluation

Blome C, Agustin M.

Volume 18 Issue 1 110-115

5 The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses

Bouwmans, Krol M, Severens, et al. *Volume 18 Issue 6 753-758* 

6 The Changing Face of the Cost-Utility Literature, 1990-2012 Neumann PT, Thorat T, Shi J, et al. Volume 18 Issue 2 271-277

7 Critical Appraisal of Network Meta-Analysis Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials

Cope S, Clemens A, Hammés F, et al. *Volume 18 Issue 2 234-249* 

8 Selecting a Dynamic Simulation Modeling Method for Health Care Delivery Research—Part 2: Report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force Volume 18 Issue 2 147-160

9 Cost –Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence

Zhong Y, Lin P-J, Cohen JT, et al. Volume 18 Issue 2 308-314

10 A Systematic Review of Generic Multidimensional Patient-Reported Outcome Measures for Children—Part 2: Evaluation of Psychometric Performance of English-Language Versions in General Populations

Janssens A, Rogers M, Thomson Coon J, et al. *Volume 18 Issue 2* 334-345